$KVAC News
Last published 1y ago
- 1y agoKVACMedera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated CardiomyopathyGlobeNewswireBOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation
- 1y agoKVACMedera's Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart SyndromeGlobeNewswireFirst-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality
- 1y agoKVACMedera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025GlobeNewswireShowcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology.FDA-backed human-based screening
- 1y agoKVACMedera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 CongressGlobeNewswireResults from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a
- 1y agoKVACMedera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 CongressGlobeNewswireBOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today
- 1y agoKVACMedera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF SummitGlobeNewswireBOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today
- 1y agoKVACMedera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection FractionGlobeNewswireBOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation
- 1y agoKVACMedera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection FractionGlobeNewswireBOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of
- 1y agoKVACMedera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, UtrechtGlobeNewswireCutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac disease
- 1y agoKVACMedera, Inc. to Participate in Two Upcoming Investor ConferencesGlobeNewswireSUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., ("Medera"), a clinical-stage biotechnology company, announced today that the management team will participate in the two upcoming investor
- 1y agoKVACMedera's Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug ScreeningGlobeNewswireInnovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart's human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio's cloud-based
- 1y agoKVACMedera's Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug TestingGlobeNewswireInnovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing protocols, setting a new
- 2y agoKVACMedera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart TechnologyPR NewswireMedera Inc. ("Medera"), a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of...
- 2y agoKVACMedera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection FractionPR NewswireMedera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-dose)....
- 2y agoKVACMedera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition CorporationPR NewswireKeen Vision Acquisition Corporation ("KVAC") (Nasdaq: KVAC, KVACW) and Medera Inc., ("Medera"), a clinical-stage biotechnology company, announced...
- 5y agoCPSRDMYQHCXYHTGC+12Hercules Capital Reports Third Quarter 2021 Financial ResultsBusiness WireRecord Q3 Total Gross Debt and Equity Commitments of $719.6 Million Record Q3 Total Gross Fundings of $431.1 Million Record Year-to-Date Total Gross Debt and Equity Commitments of $1.69 Billion Record Year-to-Date Total Gross Fundings of $1.07
- 5y agoACTCASPLBASECPSR+19Hercules Capital Reports Second Quarter 2021 Financial ResultsBusiness WireRecord Year-to-Date Total Debt and Equity Commitments of $971.7 Million Record Year-to-Date Total Fundings of $634.0 Million Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception Q2 2021 Net Asset Value per Share Increase